Surprisingly rapid regrowth of unused brain connections after decades of near blindness
Since 2007, clinical trials using gene therapy have resulted in often-dramatic sight restoration for dozens of children and adults who were otherwise doomed to blindness. Now, researchers from the Perelman School of Medicine at the University of Pennsylvania and The Children’s Hospital of Philadelphia (CHOP), have found evidence that this sight restoration leads to strengthening of visual pathways in the brain, published this week in Science Translational Medicine.
“The patients had received the gene therapy in just one eye (their worse seeing eye), and though we imaged their brains only about two years later, on average, we saw big differences between the side of the brain connected to the treated region of the injected eye and the side connected to the untreated eye,” said lead author Manzar Ashtari, PhD, director of CNS Imaging at the Center for Advanced Retinal and Ocular Therapeutics in the Department of Ophthalmology at Penn. Ashtari is the former director of Diffusion Tensor Image Analyses and Brain Morphometry at CHOP.
“It’s an elegant demonstration that these visual processing pathways can be restored even long after the period when it was thought there would be a loss of plasticity,” said senior author Jean Bennett, MD, PhD, the F.M. Kirby Professor of Ophthalmology at Penn and director of the Center for Advanced Retinal and Ocular Therapeutics.
The team examined ten patients who have Leber’s congenital amaurosis Type 2 (LCA2), a rare disease that afflicts those who inherit a bad copy of an LCA2 gene from each parent, LCA2 causes their retinas to degenerate slowly and they typically have limited visual function at birth and then experience progressive loss of their remaining vision, rendering them completely blind by mid-life.
In one of the first great success stories for gene therapy, Bennett’s team and others demonstrated the effectiveness of LCA2 gene augmentation in animal tests stretching back to the early 2000s. The basic strategy is to inject a harmless virus that inserts good copies of the normal LCA2 gene into retinal cells. Patients who have received the gene therapy have commonly gone from being blind or near blind to being partially sighted and able to navigate almost normally.
One question hanging over the field has been: even if retinal function improves, how well can the brain’s visual processing pathways recover, after years of near-total blindness in which those unused pathways inevitably will have weakened?
Ashtari, a neuroimaging specialist, addressed this question with several experiments. First she compared the LCA2 group, which had initially received the gene therapy in one eye for safety reasons, to an age-matched control group with normal vision.
Using an advanced method of MRI technique to uncover deep brain connections, she found that while the connectivity of the visual pathway from the treated eye in LCA2 patients was similar to that of sighted controls, the untreated eye showed weaker connectivity to the brain as compared to the connections for the treated side. The data showed that the retina-brain pathways in the treated eyes in the LCA2 group seemed nearly as robust as the corresponding pathways in the sighted control group, implying that these pathways had largely rebuilt themselves in the LCA2 patients, following their retinal intervention.
“That was what we expected to see— the more the treated eye sees the world and interacts with the environment the more it stimulates the pathway and the stronger the connecting pathway becomes between the retina and the brain,” said Ashtari.
The result came despite the fact that many of the LCA2 patients were in their 20s, and one was even 45—an age when the ability of the nervous system to rewire itself is thought to be greatly reduced.
Ashtari also found a strong hint in the data that the treated-eye pathways tended to be in better shape when more time had elapsed since the treatment, implying that these pathways continue to improve with use. By contrast, the untreated-eye pathways showed a clear decline with time.
The Latest on: Vision-Restoring Gene Therapy
[google_news title=”” keyword=”Vision-Restoring Gene Therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Vision-Restoring Gene Therapy
- Restoring sight is possible now with optogeneticson April 23, 2024 at 3:30 am
Several companies are experimenting with optogenetics to create a “bionic eye” that can restore sight in visually impaired people.
- 4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacityon April 9, 2024 at 5:41 am
Press Release4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity Long-Term Partnership Agreed with Beacon ...
- Advanced therapy CDMO Ascend nabs Florida manufacturing site and team from ocular gene therapy outfit Beaconon April 9, 2024 at 3:59 am
Though gene therapy manufacturing specialist ... Beacon’s advanced therapeutics are being designed to potentially restore patients’ vision or prevent disease progression, according to Ascend ...
- Gene Therapy, DNA's Past, RNA's Future: The Lost Yearson March 31, 2024 at 8:25 am
In 1999, I defined regenerative medicine as the collection of interventions that restore ... for gene therapy, with efforts around the globe pushing boundaries, driven by the audacious vision ...
- Gene therapy from RTP biotech improves vision in clinical studyon March 27, 2024 at 5:01 pm
But 30 days after receiving the gene therapy, the subject's vision improved and, for the first time, they could read the largest letters on an eye exam chart. Opus continued to enroll the next two ...
- Nanoscope eyes market after gene therapy restores vision for patients with retinal diseaseon March 26, 2024 at 12:00 am
which take aim at a specific gene mutation in the outer retinal cells, Nanoscope’s therapy is designed to target inner retinal neurons to restore vision lost as RP progresses. Nanoscope is also ...
- Nanoscope preps filing for retinitis pigmentosa gene therapyon March 25, 2024 at 5:00 pm
In RESTORE, a once-off administration of the gene therapy led to a “clinically ... which signifies a marked improvement in vision. That was sustained for 76 weeks in patients getting the high ...
- A new study to be conducted in space will test a novel gene therapy for vision losson March 14, 2024 at 5:00 pm
The gene therapy enhances cellular response to oxidative stress and prevents retinal cell death, an approach that aims to restore the functionality of damaged cells and prevent vision loss. "As we age ...
- The Bionic Eye That Could Restore Vision (and Put Humans in the Matrix)on May 17, 2023 at 5:53 pm
The microLED device, which Science Corp. calls FlexLED, is just one component of the Science Eye. For it to restore even this form of vision to patients, the Science Corp. team first needs to ...
via Bing News